The dream and reality of histology agnostic cancer clinical trials

Molecular Oncology

Volumn 8, Issue 6, 2014, Pages 1057-1063

  Lacombe, Denis ^a   Burock, Susen ^a   Bogaerts, Jan ^a   Schoeffski, Patrick ^b   Golfinopoulos, Vassilis ^a   Stupp, Roger ^a,c  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer clinical trials; Histology agnostic clinical trials

Indexed keywords

ANATOMICAL VARIATION; ARTICLE; CANCER CELL; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; EPIGENETICS; GENE EXPRESSION; GENOMICS; HISTOLOGY; HISTOLOGY AGNOSTIC CANCER CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; META ANALYSIS (TOPIC); METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NOMENCLATURE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; STUDY DESIGN; TRANSLATIONAL RESEARCH; DISEASE COURSE; PATHOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HISTOLOGICAL TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84914156660     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.002     Document Type: Article

References (41)

1. Brastianos P.K., Carter S.L., Santagata S., et al. Genomic characterization of brain metastases and paired primary tumors reveals patterns of clonal evolution. Eur. J. Cancer 2014, 49:S1-S6. (abstr).
2. Bronchud M.H., Castillo S., Escriva de R.S., et al. HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report. Onkologie 2012, 35:776-779.
3. Burock S., Meunier F., Lacombe D. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?. Eur. J. Cancer 2013, 49:2777-2783.
4. Burock S., Bean J., Lacombe D. The Evolving Clinical Trials Landscape: Perspective of the EORTC 2013, 14-16.
5. Cancer research UK: Stratified Medicine Programme. http://www.cancerresearchuk.org/science/research/how-we-deliver-our-research/others/by-programme/stratified-medicine-programme/.
6. Cappuzzo F., Bemis L., Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N.Engl. J. Med. 2006, 354:2619-2621.
7. Carr L.L., Mankoff D.A., Goulart B.H., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 2010, 16:5260-5268.
8. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516.
9. Ciriello G., Miller M.L., Aksoy B.A., et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 2013, 45:1127-1133.
10. Crown J.P., Dieras V., Staroslawska E., et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J.Clin. Oncol. 2013, 31:2870-2878.
11. Curigliano G., Pivot X., Cortes J., et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013, 22:650-656.
12. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
13. Dror M.M., Regan M.M., Oh W.K., et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 2009, 20:913-920.
14. Eichler H.G., Oye K., Baird L.G., et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 2012, 91:426-437.
15. ESMO Rationally-selected Therapeutics, Based on the Analysis of Matched Tumour and Normal Biopsies, for Patients with Advanced Malignancies 2013.
16. European Medicines Agency: Guideline on the evaluation of anticancer medicinal products in man. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf.
17. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49:1374-1403.
18. Gatta G., van der Zwan J.M., Casali P.G., et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer 2011, 47:2493-2511.
19. Grivas P.D., Daignault S., Tagawa S.T., et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2013.
20. Heinrich M.C., Joensuu H., Demetri G.D., et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin. Cancer Res. 2008, 14:2717-2725.
21. Institut National du Cancer: Le programme AcSé. http://www.e-cancer.fr/recherche/acces-aux-molecules-innovantes/le-programme-acse.
22. Kadowaki S., Yatabe Y., Hirakawa H., et al. Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma. Case Rep. Oncol. 2013, 6:450-455.
23. Kim K.B., Cabanillas M.E., Lazar A.J., et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013, 23:1277-1283.
24. Kopetz S., Desai J., Chan E., et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J.Clin. Oncol. 2010, 28.
25. Kreisl T.N., Smith P., Sul J., et al. Continuous daily sunitinib for recurrent glioblastoma. J.Neurooncol 2013, 111:41-48.
26. Law L.Y. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J.Clin. Oncol. 2012, 30:e271-e273.
27. Lillie E.O., Patay B., Diamant J., et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Per Med. 2011, 8:161-173.
28. McCaughan M. Personalized Medicine: Making Rare Cancers Less Rare 2011.
29. Perrone Matthew FDA Approved 27 New Drugs in 2013 2014.
30. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
31. Santini D., Vincenzi B., Venditti O., et al. Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?. Future Oncol. 2013, 9:1809-1811.
32. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N.Engl. J. Med. 2013, 368:2385-2394.
33. Sleijfer S., Bogaerts J., Siu L.L. Designing transformative clinical trials in the cancer genome era. J.Clin. Oncol. 2013, 31:1834-1841.
34. Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag. Res. 2013, 9:1-3.
35. Taking pan-cancer analysis global. Nat. Genet. 2013, 45:1263.
36. U.S. Food and Drug Administration Center for Drug and Research Approved Drugs 2013 2014.
37. Varmus's remarks at the AACR. Cancer Lett. 2013, 39:6-12.
38. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013, 3:120144.
39. Weinstein J.N., Collisson E.A., Mills G.B., et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 2013, 45:1113-1120.
40. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat. Med. 2013, 19:655.
41. Yi J.H., Lee J., Lee J., et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br. J. Cancer 2012, 106:1469-1474.